###begin article-title 0
VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation
###end article-title 0
###begin p 1
Conceived and designed the experiments: MRD DGD DF RKJ. Performed the experiments: MRD DGD SSC. Analyzed the data: MRD DGD SSC DF RKJ. Contributed reagents/materials/analysis tools: RKJ. Wrote the paper: MRD DGD RKJ.
###end p 1
###begin p 2
Current address: Department of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America
###end p 2
###begin p 3
###xml 822 829 822 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 903 908 <span type="species:ncbi:10090">mouse</span>
The role of vascular endothelial growth factor receptor 1 (VEGFR1/Flt1) in tumor metastasis remains incompletely characterized. Recent reports suggested that blocking VEGFR1 activity or the interaction with its ligands (VEGF and PlGF) has anti-tumor effects. Moreover, several studies showed that VEGFR1 mediates tumor progression to distant metastasis. All these effects may be exerted indirectly by recruitment of bone marrow-derived cells (BMDCs), such as myeloid cells. We investigated the role of VEGFR1 activity in BMDCs during the pre-metastatic phase, i.e., prior to metastatic nodule formation in mice after surgical removal of the primary tumor. Using pharmacologic blockade or genetic deletion of the tyrosine kinase domain of VEGFR1, we demonstrate that VEGFR1 activity is not required for the infiltration of de novo myeloid BMDCs in the pre-metastatic lungs in two tumor models and in two mouse models. Moreover, in line with emerging clinical observations, we show that blockade of VEGFR1 activity neither prevents nor changes the rate of spontaneous metastasis formation after primary tumor removal. Prevention of metastasis will require further identification and exploration of cellular and molecular pathways that mediate the priming of the metastatic soil.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 434 437 434 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer1">[1]</xref>
###xml 439 442 439 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Ferrara1">[2]</xref>
###xml 444 447 444 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Jain1">[3]</xref>
###xml 657 660 657 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Rafii1">[4]</xref>
###xml 763 766 763 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-deVisser1">[5]</xref>
###xml 768 771 768 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Pollard1">[6]</xref>
###xml 961 964 961 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer2">[7]</xref>
###xml 1078 1081 1078 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Casanovas1">[8]</xref>
###xml 1355 1356 1355 1356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1414 1417 1414 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Kamoun1">[9]</xref>
VEGF, and more recently, PlGF, have been shown to play important roles in tumor angiogenesis in preclinical studies. Moreover, VEGF is a clinically validated target for antiangiogeneic therapy for cancer, and agents that block PlGF or the tyrosine kinase activity of their cognate receptor VEGFR1 are currently approved for cancer treatment or in clinical trials (sunitinib, sorafenib, cediranib, axitinib, pazopanib, BIBF1120, etc.) [1], [2], [3]. In addition to the roles of VEGFR1 activation in tumor endothelial cells, it has been hypothesized that VEGFR1 activation mediates the mobilization of bone marrow-derived cells (BMDCs) into blood circulation [4]. Other studies have shown that BMDCs are recruited to certain tumors and facilitate tumor progression [5], [6]. A recent study demonstrated that PlGF, a ligand for VEGFR1 as well as Neuropilins 1 and 2 (NRP1/2), significantly modulated the recruitment of macrophages, tumor growth and local invasion [7]. On the other hand, blockade of VEGFR1 did not affect BMDC accumulation or growth of pancreatic endocrine tumors [8]. Moreover, VEGFR1 blockade may differentially affect the recruitment of various BMDC populations in tumors. For example, cediranib, an agent that potently inhibits VEGFR1 activity, transiently reduced macrophage infiltration but increased the total number of myeloid (CD11b+) cells and did not delay the growth rate of brain tumors [9]. Thus, the benefit of targeting VEGFR1 activity remains unclear, and is likely to be highly tumor-, BMDC type- and context-dependent.
###end p 5
###begin p 6
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt1</italic>
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Kaplan1">[10]</xref>
###xml 625 626 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Erler1">[11]</xref>
###xml 800 803 800 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer1">[1]</xref>
###xml 805 809 805 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Gerber1">[12]</xref>
###xml 1029 1033 1029 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Kaplan1">[10]</xref>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
In addition to effects at the primary tumor site, blockade of VEGFR1 has been proposed as an anti-metastasis approach. Previous studies in flt1-tk deficient mice have shown that MMP-9 is induced by VEGFR1 signaling in lung cells and facilitates metastatic tumor growth in experimental metastasis models (i.e., after intravenous infusion of cancer cells). Moreover, it has been recently reported that BMDCs - systemically mobilized in response to primary tumor growth - home to the lungs and form "pre-metastatic niches" in lungs even prior to the arrival of metastatic cancer cells [10]. A critical mediator of myeloid (CD11b+) BMDC recruitment to the "pre-metastatic niche" was shown to be hypoxia-induced lysyl oxidase [11]. Hypoxia is known to induce VEGF, PlGF, and their cognate receptor VEGFR1 [1], [12]. In a recent study, blockade of VEGFR1 with a specific antibody, MF1 (ImClone Systems, Inc.) has been shown to inhibit lung infiltration by BMDCs, subsequent "pre-metastatic niche" formation and metastatic tumor growth [10].
###end p 6
###begin p 7
###xml 119 123 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Duda1">[13]</xref>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Gao1">[14]</xref>
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Ohtaki1">[15]</xref>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Padua1">[16]</xref>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Duda1">[13]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Gao1">[14]</xref>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 179 184 <span type="species:ncbi:9606">human</span>
Spontaneous metastasis formation can be induced in preclinical models by surgically removing metastatic primary tumors [13], [14], [15], [16]. This model, relevant for resectable human cancers, has been extensively used to study the process of metastasis, including the role of BMDCs [13], [14]. In this model, we found that blockade of VEGFR1 activity did not affect the rate of spontaneous metastasis formation after primary tumor removal [17]. Here, we show that myeloid (CD11b+) BMDCs (e.g., pulmonary alveolar macrophages), are present in normal lungs and that VEGFR1 blockade does not modulate their infiltration in the presence of primary tumors prior to metastasis formation. On the other hand, we show that BMDCs may be affected by VEGFR1 activity blockade at later time-points, i.e., during metastatic tumor growth. Thus, while VEGFR1 activity is not required for the formation of metastatic tumor nodules, its blockade may differentially modulate the BMDC infiltration and growth of primary tumors and metastatic nodules.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 9
###begin p 10
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flt-1</italic>
###xml 130 135 130 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 224 229 224 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Hiratsuka1">[18]</xref>
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Hiratsuka2">[19]</xref>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 530 535 530 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
C57BL and Actb-GFP/C57BL mice (constitutively expressing GFP) were obtained from the Jackson Laboratory (Bar Harbor, Maine). Flt-1TK-/-/C57BL mice were backcrossed to 99.9% C57BL strain background (N10 equivalent) from flt-1TK-/- mice [18], [19], kindly provided by Dr. M. Shibuya, University of Tokyo, Japan. Strain background was verified by the Jackson Laboratory's Speed Congenic Development Service (The Jackson Laboratory, Bar Harbor, Maine). All mice were bred and maintained in sterile barrier animal facilities. All flt-1TK-/-/C57BL mice were used for experiments after genotyping to confirm the deletion of the intracellular domain of VEGFR1. All animal experiments were performed after obtaining approval from the Subcommittee for Research and Animal Care of the Massachusetts General Hospital.
###end p 10
###begin title 11
Bone Marrow Transplantation
###end title 11
###begin p 12
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">137</sup>
###xml 321 329 321 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Duda1">[13]</xref>
###xml 367 376 367 376 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 367 376 367 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g001"><bold>Figure 1A</bold></xref>
###xml 610 611 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 634 642 634 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 943 952 943 952 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 943 952 943 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g001"><bold>Figure 1B</bold></xref>
###xml 6 10 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
###xml 839 843 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
C57BL mice (6-7 weeks old, male) were lethally irradiated (137Cs Irradiator; Atomic Energy of Canada Ltd, Mississauga, Canada) using two 6 Gy fractions (with less than 12 hour time interval between dosing) delivered to the whole body. Irradiated mice were rescued 24 hours later by a bone marrow transplant isolated from Actb-GFP/C57BL, as previously described [13] (Figure 1A). We used the model after confirming that no weight loss or fibrosis, inflammation or any other sign of damage was detectable in the lungs two months after BMT. The BMT protocol was also optimized to ensure reproducible levels of GFP+ BMDC chimerism in BMT-Actb-GFP/C57BL mice. Blood was collected at four and eight weeks after BMT for flow cytometry analysis. To limit the variability in GFP-BMDC chimerism, BMT mice were prepared in large groups (32 recipient mice were injected with pooled BM from 11 donor mice). One group was prepared for each tumor model (see Figure 1B).
###end p 12
###begin title 13
Experimental design.
###end title 13
###begin p 14
###xml 154 162 154 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 923 924 923 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1063 1064 1063 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 175 178 <span type="species:ncbi:10090">BMT</span>
###xml 181 184 <span type="species:ncbi:10090">BMT</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
###xml 460 463 <span type="species:ncbi:10116">rat</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 938 941 <span type="species:ncbi:10090">BMT</span>
###xml 942 947 <span type="species:ncbi:10090">mouse</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
###xml 973 976 <span type="species:ncbi:10090">BMT</span>
###xml 1104 1109 <span type="species:ncbi:10090">Mouse</span>
###xml 1147 1150 <span type="species:ncbi:10116">rat</span>
###xml 1208 1213 <span type="species:ncbi:10090">mouse</span>
(A) Timeline for spontaneous metastasis studies: C57BL mice were lethally irradiated and transplanted 24 hours later with bone marrow cells isolated from Actb-GFP/C57BL mice (BMT). BMT mice were allowed to recover for 8 weeks prior to study. LLC1 or B16 tumor cells (TCs) were subcutaneously (s.c.) implanted in the left leg. Three days after LLC1 or B16 injection and until sacrifice, mice were treated 3 times per week by intraperitoneal (i.p.) injection of rat IgG (control) or VEGFR1-blocking antibody (MF1, 20 mg/kg). Primary tumors were resected when they reached a maximum length of 10 mm. Lung tissue was isolated from mice at three time points: at time of primary tumor resection and 10 and 14 days after removal of the primary tumor. Note: Tumor growth varied from 13-17 days; no macroscopic metastases are detectable at days 0 or 10 after tumor resection. (B) Bone marrow chimerism (each blue line represents GFP+ BMDCs in one BMT mouse, 30 mice prepared in one BMT procedure). Blood flow cytometric analysis was used to enumerate the percentage of GFP+ BMDCs among nucleated blood cells. (C) Mouse brain endothelial cells treated with rat IgG or MF1 were stimulated with 100 ng/ml of recombinant mouse PlGF-2 and incubated with anti-VEGFR1 antibody (MF1). VEGFR1 was immunoprecipitated and the ratio of phosphorylated-VEGFR1 to total VEGFR1 was compared to the ratio calculated for non-stimulated endothelial cells (assigned the value of 1). MF1 inhibited VEGFR1 phosphorylation in endothelial cells after PlGF2 stimulation in a dose-dependent manner.
###end p 14
###begin title 15
Tumor Cells
###end title 15
###begin p 16
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
###xml 250 256 <span type="species:ncbi:9913">bovine</span>
Lewis lung carcinoma (LLC1/LL2, CRL-1642) and B16 melanoma cell lines (CRL-6323) - both syngeneic to C57BL mouse - were purchased from ATCC (Manassas, VA). Both cell lines were propagated in DMEM (LLC1-ATCC/B16F1-Cellgro) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA).
###end p 16
###begin title 17
Tumor Growth and Metastasis Model
###end title 17
###begin p 18
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 119 124 119 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 355 356 351 352 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</bold>
###xml 74 77 <span type="species:ncbi:10090">BMT</span>
###xml 108 111 <span type="species:ncbi:10090">BMT</span>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
LLC1 or B16 cells were subcutaneously (s.c.) implanted in the left leg of BMT-Actb-GFP/C57BL (8 weeks after BMT), flt-1TK-/-/C57BL or C57BL mice as a 50 microl concentrated cell solution containing 300,000 cells in sterile PBS. Tumor growth was measured with a caliper three times per week and tumor volume (V) was calculated using the following formula (1):
###end p 18
###begin p 19
###xml 331 340 331 340 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 331 340 331 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g001"><bold>Figure 1A</bold></xref>
###xml 750 758 750 758 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 750 758 750 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g002"><bold>Figure 2</bold></xref>
###xml 79 83 <span type="species:ncbi:10090">Mice</span>
Primary tumors were surgically resected when they reached a diameter of 10 mm. Mice were sacrificed by pentobarbital overdose (200 mg/kg administered by i.p. injection) at the time of resection (i.e., day 0), or 10 or 14 days after resection to analyze BMDC infiltration and metastatic nodule formation in the lungs (see schema in Figure 1A). Prior to sacrifice, blood was collected from anesthetized animals by cardiac puncture using a 26-G needle. The lungs were washed by cardiac injection of 15 ml of PBS, weighed and then examined using a dissecting microscope. The number of macroscopic metastases was enumerated by counting individual nodules with a cell counter. B16 metastases are easily identifiable, in part due to their pigmentation (see Figure 2). Primary tumor tissues and whole lungs were fixed in 4% paraformaldehyde at 4degreesC for 6 hours, dehydrated in 30% sucrose overnight, and embedded in OCT into frozen samples for immunofluorescence histological analyses.
###end p 19
###begin title 20
Effect of VEGFR1-blockade on metastasis.
###end title 20
###begin p 21
###xml 454 458 <span type="species:ncbi:10090">mice</span>
Representative images of lung metastases 14-16 days after resection of the primary tumor and bone marrow-derived cell (BMDC) accumulation in the primary tumor, peri-metastatic lung (PML, tissue surrounding lung metastases) and lung metastases in the LLC1 (A) and B16 (B) models. The number of BMDCs was calculated as the ratio of green fluorescence protein (GFP)-surface area to DAPI-surface area. DAPI was used to stain the nuclei of all cells (n = 6-8 mice per group). All images are 512 microm across.
###end p 21
###begin title 22
Antibody Treatment
###end title 22
###begin p 23
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Wu1">[20]</xref>
###xml 247 256 247 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 247 256 247 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g001"><bold>Figure 1B</bold></xref>
###xml 1340 1349 1328 1337 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 1340 1349 1328 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g001"><bold>Figure 1C</bold></xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 357 360 <span type="species:ncbi:10116">rat</span>
###xml 470 475 <span type="species:ncbi:10090">mouse</span>
###xml 578 581 <span type="species:ncbi:10116">rat</span>
###xml 689 694 <span type="species:ncbi:10090">mouse</span>
Tumor-bearing mice were administered i.p. MF1 blocking monoclonal antibodies against VEGFR1 (a gift from ImClone Systems, New York, NY) at a blocking dose of 20 or 40 mg/kg three times per week (see Ref. [20]) from the time of tumor implantation (Figure 1B). As a control, tumor-bearing mice were treated i.p. 3 times per week with 20 mg/kg of non-specific rat IgG (Jackson ImmounoResearch Laboratories, West Grove, PA). To confirm MF1 inhibitory activity, we incubated mouse brain endothelial cells (bEnd.3 cells) in serum free condition overnight. After 1 hr of exposure with rat IgG (50 microg/ml) or MF1 (20 microg/ml or 50 microg/ml), cells were stimulated with 100 ng/ml recombinant mouse PlGF-2 (Minneapolis, MN) for 10 min. Then, the cells were rinsed with cold PBS and collected using RIPA buffer supplemented with protease inhibitors (Roche, Nutley, NJ) and phosphatase inhibitiors cocktail (Sigma, St. Louis, MO). Protein extracts were incubated with anti-VEGFR1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) overnight and VEGFR1 was precipitated using protein A agarose. Immunoprecipitates were separated on denaturing gel and transferred to PVDF membrane. Phosphotyrosine was detected using anti-phosphotyrosine antibody (Millipore, Billerica, MA). The membrane was then stripped and re-probed with anti-VEGFR1 antibody (Figure 1C).
###end p 23
###begin title 24
Histological Analysis
###end title 24
###begin p 25
###xml 1205 1210 <span type="species:ncbi:10090">mouse</span>
Frozen tumor and lung tissue samples were cryosectioned into 10-20 microm slices. Tissue sections were immunostained with monoclonal antibodies against CD11b-PE, F4/80-PE, and CD31-APC (all from BD Pharmingen, San Diego, CA). For VEGFR1 staining, we used MF1 antibodies labeled with Alexa-Flour-647 (Molecular Probes, Carlsbad, CA). All tissue sections were mounted on glass coverslips using Vectashield(R) mounting media with DAPI from Vector Labs (Burlingame, CA). For quantitative analysis, we collected 6-12 random 8-bit images per section of lung (6 per region of the lung, including lung metastasis and tissue surrounding metastasis) and tumor tissue (6 images of the periphery and 6 images of the center) (1024x1024 pixels), using a confocal microscope (Olympus, Center Valley, PA) and a 20x water-immersion lens (0.95NA). For each image, we determined the area occupied by GFP-positive BMDCs or immunostained cells normalized by area of DAPI-stained cells (nuclear counterstaining) using an algorithm written for Matlab software. The mean ratio of GFP to DAPI coverage area was calculated as a measure of cell number per tissue area. We report the average of the mean values of GFP/DAPI ratio for mouse lungs or tumors in each treatment group (6-7 lungs or tumors per treatment group were included).
###end p 25
###begin title 26
Flow Cytometric Analyses
###end title 26
###begin p 27
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Duda1">[13]</xref>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Blood was collected from mice by cardiac puncture. Tumor tissues were digested into a single cell suspension using collagenase type II (Worthington, Lakewood, NJ) [13]. Cells were immunostained with the following monoclonal antibodies: anti-CD11b-APC, anti-Gr-1-FITC/PE, anti-CXCR4-PE, anti-CD45-PerCP (all from BD Pharmingen) and MF1-Alexa-647. We used Fc-blocking antibodies (BD Pharmingen) to block non-specific binding and non-specific fluorescently labeled IgG as control.
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
Two-tailed unpaired students t-tests (assuming unequal variances) were used to compare all treatment and control groups with p<0.05 indicating a statistical difference. The rate of spontaneous metastasis formation in control and treatment groups was also compared using the Mann-Whitney U test (Wilcoxon rank-sum test).
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
Effect of VEGFR1 blockade on primary tumor growth
###end title 31
###begin p 32
###xml 101 109 101 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 188 198 188 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006525.s001">Figure S1A</xref>
###xml 188 200 188 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0006525.s001">Figure S1A</xref>,B</bold>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 260 265 260 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 295 305 295 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006525.s001">Figure S1C</xref>
###xml 295 305 295 305 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0006525.s001">Figure S1C</xref></bold>
###xml 374 379 374 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 379 384 379 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 423 433 423 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006525.s001">Figure S1D</xref>
###xml 423 433 423 433 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0006525.s001">Figure S1D</xref></bold>
###xml 97 100 <span type="species:ncbi:10090">BMT</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
Continuous blockade of VEGFR1 with MF1 antibodies - from the time of LLC1 or B16 implantation in BMT-Actb-GFP/C57BL mice - did not delay primary tumor growth compared to non-specific IgG (Figure S1A,B). Similarly, LLC1 tumor growth rate was comparable in flt-1TK-/-/C57BL to that in C57BL mice (Figure S1C). The growth of B16 melanoma was delayed by an average of 2 days in flt-1TK-/-/C57BL compared to C57BL mice (p<0.05, Figure S1D). Thus, blockade of VEGFR1 activity leads to a slight or no growth delay in primary B16 and LLC1 tumors. Since VEGFR1 is thought to modulate BMDCs recruitment to tumors and metastasis, we measured next the number of metastases that formed in the lungs after surgical removal of the primary tumors.
###end p 32
###begin title 33
Effect of VEGFR1 blockade on spontaneous metastasis formation after primary tumor resection
###end title 33
###begin p 34
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 496 504 496 504 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 496 504 496 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g002"><bold>Figure 2</bold></xref>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 936 940 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
###xml 783 787 <span type="species:ncbi:10090">mice</span>
We surgically removed the primary tumors - as per animal protocol - when LLC1 and B16 tumors grew to 10-mm in diameter (approximately 15-17 days after implantation). Two weeks after resection of primary tumors, metastatic tumor nodules were present in the lungs of all 17 mice bearing LLC1 tumors, both after MF1 (n = 9) and IgG (n = 8) treatment (see data reported in Ref. [17]). The metastatic nodules (with sizes estimated as 1-3 mm, 3-5 mm, >5 mm) were counted using a dissecting microscope (Figure 2). At this time-point, there were no significant differences between the number nor the size of metastatic nodules [17]. At the same time-point after resection of primary B16 tumors, 9/12 mice treated with MF1 and 9/13 mice treated with IgG developed lung metastatic nodules. In mice that developed macroscopic metastases, there was no significant difference between the numbers of nodules in the MF1-treated and IgG-treated groups [17]. Thus, in this setting of neoadjuvant and adjuvant VEGFR1 blockade (i.e., continuous blockade of VEGFR1 using MF1 from the time of primary tumor implantation) did not significantly alter the rate of spontaneous macroscopic lung metastasis formation.
###end p 34
###begin p 35
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 110 115 110 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 204 208 204 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Hiratsuka1">[18]</xref>
###xml 296 301 296 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 301 306 301 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 438 443 438 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 1012 1017 1012 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1017 1022 1017 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1044 1048 1044 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 332 336 <span type="species:ncbi:10090">mice</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
###xml 1039 1043 <span type="species:ncbi:10090">mice</span>
Next, we measured metastatic nodule formation after resection of LLC1 or B16 primary tumors implanted in flt-1TK-/-/C57BL mice (mice which lack the tyrosine kinase domain but not the extracellular domain [18]) or in C57BL mice. When evaluated at 14 days after primary LLC1 tumor resection, 12/13 flt-1TK-/-/C57BL mice and 6/8 C57BL mice had macroscopic lung metastases. At the same time-point after B16 primary tumor resection, 7/14 flt-1TK-/-/C57BL mice and 6/8 C57BL mice had metastatic nodules in the lung (see data reported in Ref. [17]). Control and treatment groups were compared using student's t-tests and rank-sum tests (Mann-Whitney U), and differences in metastatic tumor formation were not significant between groups. Thus, genetic ablation of VEGFR1 activity did not result in significantly different rate of formation of macroscopic lung metastasis. Similarly, the number of spontaneous macroscopic lung metastases formed 2 weeks after LLC1 or B16 resection was not significantly different between flt-1TK-/-/C57BL and C57BL mice [17].
###end p 35
###begin title 36
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The number of circulating VEGFR1+ and CXCR4+ BMDCs is tumor-dependent, but blockade of VEGFR1 activity does not change BMDC accumulation in the primary tumor
###end title 36
###begin p 37
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 304 309 304 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 388 389 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 396 397 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 403 404 403 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 412 413 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 422 423 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 445 454 445 454 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 445 454 445 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g003"><bold>Figure 3A</bold></xref>
###xml 515 516 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 991 992 991 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1056 1057 1056 1057 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1088 1093 1088 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1093 1098 1093 1098 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1240 1241 1240 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1352 1357 1352 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1357 1362 1357 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1385 1394 1385 1394 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 1385 1394 1385 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g003"><bold>Figure 3B</bold></xref>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 1115 1119 <span type="species:ncbi:10090">mice</span>
###xml 1379 1383 <span type="species:ncbi:10090">mice</span>
Several studies have shown that VEGFR1 modulates BMDC infiltration in tumors, and that BMDCs are modulating metastasis. Thus, we measured the accumulation of BMDCs in the primary tumors and lungs after the formation of macroscopic metastases in our model. Evaluation of blood cells in tumor-bearing flt-1TK-/-/C57BL and C57BL mice showed no significant difference between circulating CD45+, CD11b+, Gr-1+, VEGFR1+ or CXCR4+ cells in these mice (Figure 3A). However, we detected significantly more circulating VEGFR1+ cells and significantly fewer circulating CXCR4+ cells in C57BL mice bearing LLC1 tumors compared to C57BL mice bearing B16 tumors. Next, we investigated the intra-tumor accumulation of BMDCs. While LLC1 or B16 cells do not express VEGFR1 (as evaluated by PCR, data not shown), certain cells in the tumor stroma might express VEGFR1 (e.g., endothelial cells). Thus, we performed flow cytometric analysis of tumor stromal cells in LLC1 and B16 tumors after gating on the CD45+ cell population. LLC1 tumors contained more hematopoietic (CD45+) cells than B16 tumor both in flt-1TK-/-/C57BL and C57BL mice. However, no statistically significant differences were found among infiltrating hematopoietic BMDCs positive for VEGFR1+ cells, Gr-1 (granulocytes/monocytes), F4/80 (macrophages) or CD11b (all myeloid cells) in the tumors grown in flt-1TK-/-/C57BL and C57BL mice (Figure 3B).
###end p 37
###begin title 38
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Flow cytometric analysis of circulating cells and tumor-homing BMDCs in tumor-bearing mice.
###end title 38
###begin p 39
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 54 59 54 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 184 185 184 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 305 310 305 310 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 514 519 514 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 699 700 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 704 705 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 837 838 837 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 868 869 868 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 873 874 873 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 650 654 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
(A) Peripheral blood from C57BL (black bars) and flt-1TK-/-/C57BL (empty bars with diagonal lines) mice were analyzed using antibodies for specific surface markers (all cells were CD45+). B, Flow cytometric analysis of enzymatically digested LLC1 tumor suspensions from C57BL (black bars, n = 6) and flt-1TK-/-/C57BL (empty bars with diagonal lines, n = 6) mice using antibodies for specific surface markers. There was no statistically significant difference in the blood cell population studied in C57BL and flt-1TK-/-/C57BL nor in the number of hematopoietic cells within the tumor tissues. However, there were significant inter-tumor differences: mice with B16 tumors had significantly more CXCR4+CD45+ blood circulating cells than mice with LLC1 tumors (p<0.05 by Student's t-test). In addition, while B16 tumors recruited fewer CD45+ cells, the fraction of VEGFR1+CD45+ cells was greater than in LLC1 tumors. A statistically significant difference (p<0.05 by Student's t-test) is identified with an asterisk.
###end p 39
###begin title 40
VEGFR1-blocking antibody reduces the accumulation of bone marrow-derived cells in the metastatic lesions and peri-metastatic lung tissue, but not in the primary tumors
###end title 40
###begin p 41
###xml 138 146 138 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 385 396 385 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A&#8211;B</bold>
###xml 385 396 385 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g004"><bold>Figure 4A&#8211;B</bold></xref>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 669 678 669 678 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figures 2</bold>
###xml 669 678 669 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g002"><bold>Figures 2</bold></xref>
###xml 683 687 683 687 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4E,L</bold>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g004"><bold>4E,L</bold></xref>
###xml 885 889 885 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Kaplan1">[10]</xref>
###xml 911 915 911 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Duda1">[13]</xref>
###xml 134 137 <span type="species:ncbi:10090">BMT</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
To establish with precision the BMDCs infiltration after VEGFR1 blockade, we quantified the BMDCs in LLC1 and B16 tumors implanted in BMT-Actb-GFP/C57BL mice after treatment with MF1 at the time of resection (approximately 2 weeks after implantation). Antibody blockade of VEGFR1 - from the time of implantation - did not change the number of GFP+ BMDCs in primary LLC1 or B16 tumors (Figure 4A-B) [17]. However, when most mice spontaneously developed macroscopic metastases (2 weeks after primary tumor resection), we detected a significant increase in BMDC accumulation inside the LLC1 metastatic nodules and in the peri-tumor lung tissue, but not in B16 metastases (Figures 2 and 4E,L). Thus, the reduction by VEGFR1 blockade in BMDC accumulation in metastases is tumor dependent. However, prior to the time-point used by us for resection (days 14-16), BMDC "pre-metastatic niches" [10], and metastatic foci [13] should have been formed in the lungs in these tumor models. Thus, we measured the accumulation of BMDCs in the lungs at the earlier time points (i.e., days 0 and 10 after resection).
###end p 41
###begin title 42
Bone marrow-derived cell (BMDC) accumulation in the primary tumors, lung metastases and surrounding (peri-metastatic) lung tissues after VEGFR1 blockade.
###end title 42
###begin p 43
###xml 141 149 141 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 137 140 <span type="species:ncbi:10090">BMT</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
Confocal images of cryo-sectioned primary tumor (A-D), peri-metastatic lung tissue (E-H) and metastatic lung tumors (I-L) collected from BMT-Actb-GFP/C57BL mice (BMDCs are shown in green) after IgG (A, C, E, G, I, K) or MF1 (B, D, F, H, J, L) treatment. Tissues were counterstained with DAPI nuclear dye (in blue). The width of images in A-J is 512 microm and images in K and L are 256 microm across.
###end p 43
###begin title 44
VEGFR1-blocking antibody does not reduce the baseline accumulation of myeloid bone marrow-derived cells in the pre-metastatic lungs
###end title 44
###begin p 45
###xml 316 324 316 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 337 345 337 345 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g005"><bold>Figure 5</bold></xref>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 706 714 706 714 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6</bold>
###xml 706 714 706 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g006"><bold>Figure 6</bold></xref>
###xml 766 777 766 777 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7A,D</bold>
###xml 766 777 766 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g007"><bold>Figure 7A,D</bold></xref>
###xml 1006 1011 1006 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1011 1016 1011 1016 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1083 1084 1083 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1157 1165 1157 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 1208 1209 1208 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1285 1290 1285 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1290 1295 1290 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1308 1319 1308 1319 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7B,E</bold>
###xml 1308 1319 1308 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g007"><bold>Figure 7B,E</bold></xref>
###xml 1359 1360 1359 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1404 1409 1404 1409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1409 1414 1409 1414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1590 1591 1590 1591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1612 1613 1612 1613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1690 1695 1690 1695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1695 1700 1695 1700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1723 1736 1723 1736 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7C,F,G</bold>
###xml 1723 1736 1723 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006525-g007"><bold>Figure 7C,F,G</bold></xref>
###xml 312 315 <span type="species:ncbi:10090">BMT</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
###xml 690 693 <span type="species:ncbi:10090">BMT</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 913 916 <span type="species:ncbi:10090">BMT</span>
###xml 1023 1027 <span type="species:ncbi:10090">mice</span>
###xml 1051 1055 <span type="species:ncbi:10090">mice</span>
###xml 1153 1156 <span type="species:ncbi:10090">BMT</span>
###xml 1172 1176 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
###xml 1431 1435 <span type="species:ncbi:10090">mice</span>
###xml 1717 1721 <span type="species:ncbi:10090">mice</span>
At the time of the primary tumor resection, as well as 10 days after that, evaluation of lungs showed no macroscopic metastatic tumor nodules. Nevertheless, BMDC infiltration at the time of resection was small but detectable in both LLC1 and B16 tumor models, and comparable with BMDC accumulation in tumor-free BMT-Actb-GFP/C57BL mice (Figure 5). Thus, VEGFR1 blockade by MF1 treatment did not reduce BMDC infiltration in the lungs prior to macroscopic metastases formation (i.e., at days 0 and 10) in mice that had primary tumors removed [17]. These BMDCs were likely pulmonary alveolar macrophages, which reside in the normal, non-irradiated lung in comparable numbers in tumor-free non-BMT C57BL mice (Figure 6). To directly address the issue of BMDC phenotype (Figure 7A,D), and to exclude the possibility that inflammatory BMDCs infiltration in lungs was an artifact due to prior whole body irradiation and BMT, we performed CD11b (Mac1) and VEGFR1 immunostaining in normal, non-irradiated C57BL and flt-1TK-/-/C57BL mice. In the lungs of these mice, we detected myeloid (CD11b+) cells in numbers comparable to those of lung infiltrating BMDCs in BMT-Actb-GFP/C57BL mice. Moreover, the number of VEGFR1+ cells in the lung tissue was not significantly different between C57BL and flt-1TK-/-/C57BL mice (Figure 7B,E). Next, we measured the number of CD11b+ cells in spontaneous metastatic nodules in flt-1TK-/-/C57BL and C57BL mice formed after primary tumor resection. Consistent with the effect of antibody blockade of VEGFR1, we detected a significant decrease in the number of CD11b+ cells but not VEGFR1+ cells in the peri-tumor areas in LLC1 lung metastases from (non-irradiated) flt-1TK-/-/C57BL and C57BL mice (Figure 7C,F,G).
###end p 45
###begin title 46
Effect of VEGFR1-blockade on BMDC infiltration in lungs prior to macroscopic metastasis formation.
###end title 46
###begin p 47
###xml 267 275 267 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 263 266 <span type="species:ncbi:10090">BMT</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
Treatment of tumor bearing mice with MF1 antibody did not change the infiltration with BMDCs in lungs at the time of primary tumor resection (day 0) or 10 days after primary tumor removal. Representative images of lung tissue from non-tumor bearing C57BL (A) and BMT-Actb-GFP/C57BL (B) mice and from LLC1-tumor bearing mice at the time of primary tumor resection (day 0) after treatment with IgG (C) or MF1 (D). The number of BMDCs was calculated as the ratio of green fluorescence protein (GFP)-surface area to DAPI-surface area (E). DAPI was used to stain the nuclei of all cells (n = 6-8 mice per group). All images are 512 microm across.
###end p 47
###begin title 48
Representative images and analysis of CD11b and MF1 staining of normal lung tissue.
###end title 48
###begin p 49
###xml 106 114 106 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 102 105 <span type="species:ncbi:10090">BMT</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
(A-H) Confocal microscopy images of lung tissue from C57BL (A-D, non-irradiated, non-GFP control) and BMT-Actb-GFP/C57BL (E-H, irradiated mice, GFP+ BMDCs shown in green) mice stained with CD11b-AF546 (red) and MF1-AF647 (yellow) and counterstained with DAPI nuclear dye (blue). The number of GFP, CD11b, or MF1 positive cells was calculated as a ratio of green, red, or yellow surface area to DAPI surface area, respectively (I). All images are 512 microm across.
###end p 49
###begin title 50
Representative images and quantification of CD11b and VEGFR1 positive cells at the periphery of lung metastases.
###end title 50
###begin p 51
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 83 88 83 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 407 408 407 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 418 419 418 419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
(A-F) Confocal microscopy images of lung tissue from C57BL mice (WT, A-C) and flt-1TK-/-/C57BL (KO, D-F) mice after immunostaining for CD11b (using FITC-labeled anti-CD11b antibody, in green in B and E), or for VEGFR1 (using AF647-labeled MF1 antibody, in red in C and F). Sections were counterstained with DAPI nuclear dye (in blue in A-F). The number of positive cells was calculated as the ratio of CD11b+ or VEGFR1+ surface area to DAPI surface area (G). A statistically significant difference (p<0.05 by Student's t-test) is identified with an asterisk. All images are 512 microm across.
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Jain1">[3]</xref>
###xml 378 381 378 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Ferrara1">[2]</xref>
###xml 560 563 560 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer1">[1]</xref>
###xml 720 723 720 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer2">[7]</xref>
###xml 897 901 897 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Hiratsuka2">[19]</xref>
###xml 1097 1101 1097 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Kaplan1">[10]</xref>
###xml 1441 1445 1441 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Wolmark1">[21]</xref>
###xml 1312 1320 <span type="species:ncbi:9606">patients</span>
###xml 1409 1417 <span type="species:ncbi:9606">patients</span>
VEGF is a clinically validated target in metastatic (advanced) cancer treatment, but the mechanism(s) by which its blockade leads to a clinical benefit remain unclear [3]. It is largely thought that the benefit derives from blockade of the interaction between VEGF and its receptor VEGFR2 on endothelial cells, which mediates key functions in angiogenesis and vascular function [2]. But VEGF binds with a higher affinity to VEGFR1, which is present on endothelial cells but also on inflammatory cells in tumors or even on the malignant cells in certain tumors [1]. Recent studies of the VEGFR1 ligand PlGF have proposed that VEGFR1 mediates tumor growth and angiogenesis by recruiting tumor-promoting inflammatory cells [7]. Others have shown that VEGFR1 signaling activation leads to MMP-9 expression in lung stromal cells, which facilitates lung metastasis in a model of experimental metastasis [19]. Moreover, it has been proposed that BMDC infiltration into lung tissue precedes the spontaneous arrival of metastatic cancer cells, and that VEGFR1 expression on the BMDCs mediates this process [10]. The direct implication is that VEGFR1 blockade may prevent/eradicate metastasis of the primary tumors to distant organs. Of note, a phase III of the anti-VEGF antibody bevacizumab as adjuvant after surgery in patients with colorectal cancer showed that VEGF blockade did not affect metastasis formation or patients' disease-free survival [21].
###end p 53
###begin p 54
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 699 704 699 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1570 1575 1570 1575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1575 1580 1575 1580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 1867 1872 1867 1872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 1872 1877 1872 1877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 2246 2250 2246 2250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Ebos1">[22]</xref>
###xml 2252 2256 2252 2256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-PaezRibes1">[23]</xref>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 711 715 <span type="species:ncbi:10090">mice</span>
###xml 775 779 <span type="species:ncbi:10090">mice</span>
###xml 1432 1436 <span type="species:ncbi:10090">mice</span>
###xml 1587 1591 <span type="species:ncbi:10090">mice</span>
###xml 1884 1888 <span type="species:ncbi:10090">mice</span>
We sought to establish if blockade of VEGFR1 activity could eradicate tumor progression to metastasis in a model mirroring the neoadjuvant and adjuvant therapy of tumors (i.e., continuous VEGFR1 blockade in mice from the time of implantation of the primary tumor, including the period after resection of the primary tumor when it has reached 1 cm in diameter and has seeded metastatic cells in the lungs). None of the cancer cell lines used in this study (LLC1 and B16) expressed detectable levels of VEGFR1. In these models, we measured the spontaneous formation of lung metastatic nodules. In addition, we studied formation of lung metastatic nodules in a genetic model of VEGFR1 deficiency (flt-1TK-/-/C57BL mice, which lack tyrosine kinase domain of VEGFR1). Since these mice express the extracellular domain of VEGFR1, the ligands can bind to the extracellular portion of the receptor, unlike when the MF1 antibodies are used (which completely block both ligand-receptor interaction and downstream signaling). Consistent with published reports on blockade of the VEGFR1 ligand PlGF, we found a significantly decreased blood vessel density in primary LLC1 tumor after VEGFR1 blockade by MF1 treatment. However, MF1 treatment did not decrease the number of BMDCs recruited into primary LLC1 tumors, nor their growth rate. Moreover, despite continued VEGFR1 blockade with MF1, metastatic nodule formation rate was not affected in mice whose tumors were resected when they reached 1 cm in diameter. These results were confirmed using the spontaneous LLC1 metastasis in flt-1TK-/-/C57BL mice. In a second model, we evaluated B16 growth and spontaneous metastasis after primary tumor resection. Similar to LLC1 tumors, tumor growth and spontaneous B16 metastatic nodule formation was not significantly affected by MF1 treatment from the time of tumor implantation. In flt-1TK-/-/C57BL mice, B16 primary tumor growth was significantly delayed compared to C57BL, but spontaneous B16 metastatic nodule formation after primary tumor resection was similar. The lack of effects of VEGFR1 antagonism on the rate of spontaneous metastasis is of particular interest in light of recent reports that VEGF antagonism might lead to increased metastatic burden [22], [23].
###end p 54
###begin p 55
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 137 140 137 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer2">[7]</xref>
###xml 281 284 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer2">[7]</xref>
###xml 579 582 579 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer1">[1]</xref>
In a study of PlGF blockade, Fischer et al. reported significant effects of anti-PlGF on the primary B16 tumors and lymphatic metastasis [7]. Data from our own experiments using PlGF blockade (Dawson et al., unpublished observations) are consistent with the results in this report [7], and suggest that the antiangiogenic effect in primary tumors may account for the effects of PlGF blockade on lymphatic metastasis and lung metastasis. It is important to note that in this case the blockade of the ligand (i.e., PlGF) may affect not only VEGFR1 activity, but also NRP1 and NRP2 [1].
###end p 55
###begin p 56
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Kaplan1">[10]</xref>
###xml 227 235 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 344 351 344 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 584 591 584 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 791 794 791 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Casanovas1">[8]</xref>
###xml 959 963 959 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Wu1">[20]</xref>
###xml 965 969 965 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Luttun1">[24]</xref>
###xml 1189 1193 1189 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Hiratsuka2">[19]</xref>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
We used the similar regimen for MF1 treatment, similar cell lines and similar mouse strain as Kaplan et al. [10]. At this dose, MF1 was "biologically active" since it significantly inhibited PlGF-induced VEGFR1 phosphorylation in vitro. Moreover, MF1 treatment significantly inhibited BMDC accumulation in and around growing metastatic nodules in vivo. Nevertheless, VEGFR1 activity blockade did not change BMDC/CD11b+ cell accumulation in pre-metastatic lungs. This may point toward a key role of the resident pulmonary alveolar macrophages in the pre-metastatic phase as opposed to de novo BMDC recruitment. The lack of effect of MF1 treatment on tumor angiogenesis and inflammatory cell infiltration has been well established for spontaneous tumors (e.g., pancreatic insulinoma, see Ref. [8]). In models in which an anti-tumor effect for VEGFR1 blockade was detected, they were attributed to direct effects on cancer cells or by modulation of angiogenesis [20], [24], but there was no data reported on hematogenous metastasis formation. This may be related to cell migration and MMP-9 activity in response to VEGFR1 activation in resident pulmonary macrophages and/or endothelial cells [19].
###end p 56
###begin p 57
###xml 103 106 103 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Fischer1">[1]</xref>
###xml 108 111 108 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Rafii1">[4]</xref>
###xml 481 489 481 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 760 765 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt-1</italic>
###xml 765 770 765 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 809 810 809 810 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1514 1518 1514 1518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Dawson1">[17]</xref>
###xml 1743 1751 1743 1751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Actb-GFP</italic>
###xml 1767 1768 1767 1768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1931 1935 1931 1935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006525-Shojaei1">[25]</xref>
###xml 477 480 <span type="species:ncbi:10090">BMT</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
###xml 777 781 <span type="species:ncbi:10090">mice</span>
###xml 1739 1742 <span type="species:ncbi:10090">BMT</span>
###xml 1758 1762 <span type="species:ncbi:10090">mice</span>
The regulation of tumor angiogenesis by VEGFR1 may be direct or indirect (related to BMDC recruitment) [1], [4]. Given the lack of modulation of metastatic nodule formation by VEGFR1 in our models, we evaluated the kinetics of BMDC infiltration in lungs prior to and after macroscopic metastatic nodule formation. We found no significant difference after blockade of VEGFR1 activity in BMDC infiltration in lungs prior to macroscopic metastasis formation. BMDC infiltration in BMT-Actb-GFP/C57BL mice was similar the CD11b+ cell infiltration in non-irradiated C57BL mice. Moreover, MF1 treatment did not significantly change the number of BMDCs in the pre-metastatic lungs of mice. This lack of modulation of BMDC infiltration in normal lungs was confirmed in flt-1TK-/-/C57BL mice, which had comparable CD11b+ cell numbers (most likely pulmonary alveolar macrophages) in pre-metastatic lungs. Nevertheless, after the onset of metastatic nodule growth, MF1 blockade of VEGFR1 led to a partial decrease in BMDC infiltration inside and around LLC1 metastatic nodules, which is consistent with modulation by VEGFR1 activity of BMDC accumulation in some tumors during their growth. Of note, despite the significant reduction, the BMDC accumulation was not completely blocked, and remained quite high, suggesting that BMDC accumulation in growing metastatic nodules is only partially controlled by VEGFR1 signaling. In growing B16 tumors, which have low levels of BMDC infiltration in both primary and metastatic sites [17], MF1 blockade of VEGFR1 did not change the number of BMDCs. Collectively, these data suggest that signaling pathways alternative to VEGFR1 are involved in BMDC infiltration in growing B16 or LLC1 tumors. Of interest, in BMT-Actb-GFP/C57BL mice, GFP+ expression in BMDCs often co-localized with expression of Gr1 or CD11b. These BMDCs have been shown to modulate resistance to VEGF blockade in these tumor models [25].
###end p 57
###begin p 58
In summary, we show that formation of the metastatic nodules is independent of intracellular VEGFR1 activity, since neither pharmacologic blockade nor genetic deficiency in intracellular VEGFR1-TK domain prevented or altered pre-metastatic BMDC infiltration, nor spontaneous metastasis. We propose that pathways other than VEGFR1 are activated and lead to BMDC infiltration, and should be targeted in order to optimize anti-VEGF therapy and prevent spontaneous metastasis.
###end p 58
###begin title 59
Supporting Information
###end title 59
###begin p 60
###xml 100 103 <span type="species:ncbi:10090">BMT</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
Primary LLC1 and B16 tumor growth kinetics after VEGFR1 blockade. LLC1 and B16 tumors were grown in BMT-Actb-GFP/C57BL mice treated with IgG (black solid lines) or MF1 (blue dashed lines) (A,C) or in C57BL (WT, black solid lines) or flt-1TK-/-/C57BL (KO, blue dashed lines) mice (B,D).
###end p 60
###begin p 61
(1.19 MB PDF)
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin p 63
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flt1</italic>
###xml 154 159 154 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TK&#8211;/&#8211;</sup>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
We thank J. Kahn, S. Roberge and C. Smith for invaluable help with animal experiments and histology. We also thank Dr. Masafumi Shibuya for providing flt1TK-/- mice and useful discussions, and ImClone Systems Inc. for generously providing MF1 antibodies.
###end p 63
###begin title 64
References
###end title 64
###begin article-title 65
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
###end article-title 65
###begin article-title 66
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
###end article-title 66
###begin article-title 67
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
###end article-title 67
###begin article-title 68
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
###end article-title 68
###begin article-title 69
Paradoxical roles of the immune system during cancer development.
###end article-title 69
###begin article-title 70
Tumour-educated macrophages promote tumour progression and metastasis.
###end article-title 70
###begin article-title 71
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
###end article-title 71
###begin article-title 72
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
###end article-title 72
###begin article-title 73
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Edema control by cediranib, a VEGF targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
###end article-title 73
###begin article-title 74
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
###end article-title 74
###begin article-title 75
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.
###end article-title 75
###begin article-title 76
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.
###end article-title 76
###begin article-title 77
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors.
###end article-title 77
###begin article-title 78
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis.
###end article-title 78
###begin article-title 79
Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor.
###end article-title 79
###begin article-title 80
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.
###end article-title 80
###begin article-title 81
VEGFR1 activity-independent metastasis formation.
###end article-title 81
###begin article-title 82
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.
###end article-title 82
###begin article-title 83
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis.
###end article-title 83
###begin article-title 84
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
###end article-title 84
###begin article-title 85
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08.
###end article-title 85
###begin article-title 86
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
###end article-title 86
###begin article-title 87
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
###end article-title 87
###begin article-title 88
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
###end article-title 88
###begin article-title 89
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.
###end article-title 89
###begin p 90
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 90
###begin p 91
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was supported by NIH grants R01CA115767 and R01CA85140 (to RKJ), and in part by grants P01CA80124 and R01CA126642 (to RKJ), R01CA96915 (to DF), R21-CA139168 (to DGD), and Federal Share/NCI Proton Beam Program Income (to RKJ and DGD).
###end p 91

